Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Lancet 400(10366):18691881 Jastreboff AM, Kaplan LM, Fras JP, Wu Q, Du Y, Gurbuz S et al (2023) Retatrutide phase 2 obesity trial investigators
Tirzepatide, known as Mounjaro for diabetes and recently approved as Zepbound for weight loss, is a newer medication that acts on two key hormones: GLP-1 and GIP
Your provider can help set expectations and determine whether treatment remains appropriate based on your medical history, symptoms, and follow-up review
In STEP 1, about 86.4% of semaglutide participants lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15% (versus 31.5%, 12.0%, and 4.9% on placebo)
US$ 29.15
US$ 20.29
US$ 28.25
